Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.835 USD | +5.94% | +13.46% | -58.09% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 14.49 | 4.95 | 2.159 | 1.703 | - | - |
Enterprise Value (EV) 1 | 14.49 | 4.95 | 2.159 | 1.703 | 1.703 | 1.703 |
P/E ratio | -0.72 x | -0.47 x | -0.23 x | -0.24 x | -0.83 x | -1.12 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 34.7 | 50.4 | 236 | 444.1 | - | - |
Reference price 2 | 417.6 | 98.16 | 9.150 | 3.835 | 3.835 | 3.835 |
Announcement Date | 3/28/22 | 2/21/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -7.857 | -9.674 | -8.042 | -13.34 | -15.73 | -16.23 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) | -7.902 | -9.611 | -7.795 | - | - | - |
Net income 1 | -10.46 | -9.611 | -7.795 | -13.2 | -15.58 | -16.06 |
Net margin | - | - | - | - | - | - |
EPS 2 | -583.2 | -208.8 | -40.05 | -16.17 | -4.610 | -3.410 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 2/21/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.553 | -2.786 | -2.731 | -2.446 | -1.712 | -2.278 | -1.732 | -1.812 | -2.22 | -3.204 | -3.006 | -3.915 | -3.215 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -2.553 | -2.786 | -2.731 | -2.425 | -1.67 | -2.24 | -1.701 | -1.719 | -2.134 | - | - | - | - |
Net income 1 | -2.553 | -2.786 | -2.731 | -2.425 | -1.67 | -2.24 | -1.701 | -1.719 | -2.134 | -3.134 | -2.914 | -3.894 | -3.259 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -194.4 | -79.20 | -57.60 | -48.00 | -28.80 | -34.05 | -9.450 | -8.100 | -3.150 | -7.050 | -3.790 | -3.730 | -1.590 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/16/22 | 8/15/22 | 11/10/22 | 2/21/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/21/24 | 5/15/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 2/21/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.09% | 1.7M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- DRMA Stock
- Financials Dermata Therapeutics, Inc.